S-enantiomerically enriched compositions of beta blockers for treating muscle weakness

Abstract

The use of S-enantiomerically enriched compositions of beta blockers for treating muscle weakness. The beta blocker can be oxprenolol or a pharmaceutically acceptable salt thereof.

1 . A method of treating muscle weakness in an individual, comprising administering to the individual an effective amount of an S-enantiomerically enriched composition of a beta blocker or a pharmaceutically acceptable salt thereof. 
     
     
         2 . A method of preventing body weight loss in an individual with muscle weakness, comprising administering to the individual an effective amount of an S-enantiomerically enriched composition of a beta blocker or a pharmaceutically acceptable salt thereof. 
     
     
         3 . A method of preventing and treating muscle wasting in an individual with muscle weakness, comprising administering to the individual an effective amount of an S-enantiomerically enriched composition of a beta blocker or a pharmaceutically acceptable salt thereof. 
     
     
         4 . A method of improving quality of life in an individual with muscle weakness, comprising administering to the individual an effective amount of an S-enantiomerically enriched composition of a beta blocker or a pharmaceutically acceptable salt thereof. 
     
     
         5 . The method of any one of  claims 1 - 4 , wherein the beta blocker is oxprenolol or a pharmaceutically acceptable salt thereof. 
     
     
         6 . The method of any one of  claims 1 - 5 , wherein the muscle weakness is in an acute state. 
     
     
         7 . The method of any one of  claims 1 - 5 , wherein the muscle weakness is localized. 
     
     
         8 . The method of any one of  claims 1 - 7 , wherein the individual has suffered a musculoskeletal injury. 
     
     
         9 . The method of any one of  claims 1 - 7 , wherein the individual has undergone surgery. 
     
     
         10 . The method of  claim 9 , wherein the surgery is abdominal, orthopedic, cardiac, brain, lung, eye, or head and neck. 
     
     
         11 . The method of any one of  claims 1 - 10 , wherein the individual has been immobilized. 
     
     
         12 . The method of any one of  claims 1 - 11 , wherein the individual has been immobilized for at least 48 hours. 
     
     
         13 . The method of any one of  claims 1 - 12 , wherein the individual has suffered a major trauma. 
     
     
         14 . The method of  claim 13 , wherein the trauma affects large bones, abdominal organs, chest organs, or head. 
     
     
         15 . The method of any one of  claims 1 - 14 , wherein the individual has suffered fractures of the long bones of the arm or leg. 
     
     
         16 . The method of any one of  claims 1 - 15 , wherein the composition comprises an enantiomeric excess of at least about 50% of S-oxprenolol or a pharmaceutically acceptable salt thereof. 
     
     
         17 . The method of  claim 16 , wherein the composition comprises an enantiomeric excess of at least about 80% of S-oxprenolol or a pharmaceutically acceptable salt thereof. 
     
     
         18 . The method of  claim 17 , wherein the composition comprises an enantiomeric excess of at least about 99% of S-oxprenolol or a pharmaceutically acceptable salt thereof. 
     
     
         19 . The method of  claim 18 , wherein the composition comprises an enantiomeric excess of at least about 99.9% of S-oxprenolol or a pharmaceutically acceptable salt thereof. 
     
     
         20 . The method of any one of  claims 1 - 19 , wherein the composition is administered orally. 
     
     
         21 . The method of any one of  claims 1 - 20 , wherein the amount of S-oxprenololor a pharmaceutically acceptable salt thereof in the composition is about 80 to about 160 mg daily. 
     
     
         22 . The method of any one of  claims 1 - 21 , wherein the composition is administered daily or twice daily. 
     
     
         23 . A pharmaceutical composition comprising a beta blocker or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier for use in treating muscle weakness. 
     
     
         24 . The pharmaceutical composition of  claim 23 , wherein the beta blocker is oxprenolol or a pharmaceutically acceptable salt thereof. 
     
     
         25 . The pharmaceutical composition of  claim 24 , wherein the composition comprises an enantiomeric excess of at least about 50% of S-oxprenolol or a pharmaceutically acceptable salt thereof. 
     
     
         26 . The pharmaceutical composition of  claim 25 , wherein the composition comprises an enantiomeric excess of at least about 80% of S-oxprenolol or a pharmaceutically acceptable salt thereof. 
     
     
         27 . The pharmaceutical composition of  claim 26 , wherein the composition comprises an enantiomeric excess of at least about 99% of S-oxprenolol or a pharmaceutically acceptable salt thereof. 
     
     
         28 . The pharmaceutical composition of  claim 27 , wherein the composition comprises an enantiomeric excess of at least about 99.9% of S-oxprenolol or a pharmaceutically acceptable salt thereof. 
     
     
         29 . A kit comprising a pharmaceutical composition comprising a beta blocker or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier and instruction for using the pharmaceutical composition for treating muscle weakness. 
     
     
         30 . The kit of  claim 29 , wherein the beta blocker is oxprenolol or a pharmaceutically acceptable salt thereof.